Business News • PR NewsWire • Uninterrupted Pradaxa® (dabigatran etexilate mesylate) Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation

Uninterrupted Pradaxa® (dabigatran etexilate mesylate) Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation

Uninterrupted Pradaxa® (dabigatran etexilate mesylate) Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation

RIDGEFIELD, Conn., March 19, 2017 /PRNewswire/ -- Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate mesylate) compared to warfarin in atrial fibrillation (AFib) patients undergoing catheter ablation. AFib patients who underwent...

View More : http://www.prnewswire.com/news-releases/uninterrupted-pradaxa-dabigatran-etexilate-mesylate-showed-less-major-bleeding-t...

Releted News by prnewswire

New price transparency for leading world bunker and fuel oil hub

Los ingresos de LONGi Green Energy Technology prácticamente se duplicaron en 2016

Společnost Intelliber Technologies spouští Socialyk - první networkingovou platformu SaaS zaměřenou na člověka

Uninterrupted Pradaxa® (dabigatran etexilate mesylate) Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation

Thirteen Companies Honored with IHA Global Innovation Awards for Product Design

InnoLight Technology Announced Volume Shipments of 17 100G QSFP28 Products and the Introduction of 400G OSFP at OFC 2017